Fractyl Labs raises $44 million in Series D to develop a treatment for type 2 diabetes

 Fractyl Labs, a Lexington, Massachusetts-based startup developing treatments for diabetes, has raised $44 million in Series D financing from a slew of VC firms, including GV, True Ventures, the IDO Fund, General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners, L.P., and Deerfield Management Company, L.P. Fractyl has been working on… Read More

from TechCrunch http://ift.tt/2Apz9Yp